NUMIF - Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer's Disease
A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease, announcing recently that it has gotten approval from Argentina’s regulators to begin a Phase ll clinical study using the Company’s unique psychedelic molecule, BMND08. Biomind Labs is a biotech research and development company looking into new medicines and nanotech delivery systems for a wide range of psychiatric and neurological diseases. The trial looks at whether BMND08, a treatment based on the natural psychedelic chemical 5-Methoxy-N,N-dimethyltryptamine (also known as 5-MeO-DMT or simply DMT), helps treat the depression and anxiety that are typical in Alzheimer’s patients. The Phase ll clinical trial will take place in Argentina, where regulators approved the investigation in May. Although some research has looked into cannabis as a possible cure for Alzheimer’s disease symptoms, Biomind’s study is thought to be the first to explore a psychedelic like DMT. Optimi Health Corp. ( CSE:OPTI ) ( OTCQX:OPTHF ) , Seelos Therapeutics ( NASDAQ:SEEL ), Numinus Wellness ( TSX:NUMI ) ( OTCQX:NUMIF ), ATAI Life Sciences ( NASDAQ:ATAI ), and Tonix Pharmaceuticals Holding Corp. ( NASDAQ:TNXP ) are other companies developing psychedelic-based treatments.
Optimi Health Corp. ( CSE:OPTI ) ( OTCQX:OPTHF ) is a homegrown Canadian company producing natural, scalable and accessible psychedelic...
Click here to read the full article on PressReach.com .Subscribe to the PressReach RSS feeds:
- Featured News RSS feed
- Investing News RSS feed
- Daily Press Releases RSS feed
- Trading Tips RSS feed
- Investing Videos RSS feed
Follow PressReach on Twitter
Subscribe to us on Youtube
PressReach Disclaimer .